ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $32.31 Average Target Price from Analysts

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has been given a consensus recommendation of “Moderate Buy” by the seventeen ratings firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $33.4412.

Several research analysts have weighed in on ACAD shares. Stifel Nicolaus lifted their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a “hold” rating in a research note on Tuesday, July 21st. HC Wainwright reaffirmed a “buy” rating on shares of ACADIA Pharmaceuticals in a report on Thursday. Royal Bank Of Canada lifted their price objective on shares of ACADIA Pharmaceuticals from $36.00 to $37.00 and gave the company an “outperform” rating in a research report on Wednesday. Oppenheimer boosted their price objective on shares of ACADIA Pharmaceuticals from $23.00 to $25.00 and gave the company a “market perform” rating in a research note on Wednesday. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $37.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Monday, June 29th.

Insider Transactions at ACADIA Pharmaceuticals

In related news, insider James Kihara sold 5,401 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total value of $114,393.18. Following the completion of the sale, the insider owned 24,509 shares in the company, valued at $519,100.62. This trade represents a 18.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth H.Z. Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $26.13, for a total value of $432,660.54. Following the completion of the sale, the executive vice president directly owned 18,994 shares in the company, valued at $496,313.22. This represents a 46.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 26.20% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

Several hedge funds have recently modified their holdings of ACAD. Norges Bank purchased a new position in ACADIA Pharmaceuticals in the fourth quarter valued at about $40,266,000. Millennium Management LLC lifted its position in shares of ACADIA Pharmaceuticals by 2,052.1% during the 3rd quarter. Millennium Management LLC now owns 1,483,235 shares of the biopharmaceutical company’s stock valued at $31,652,000 after acquiring an additional 1,414,315 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of ACADIA Pharmaceuticals by 390.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company’s stock worth $35,187,000 after acquiring an additional 1,312,426 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of ACADIA Pharmaceuticals by 47.3% during the 1st quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock worth $74,435,000 after acquiring an additional 1,073,834 shares in the last quarter. Finally, Logos Global Management LP acquired a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter worth approximately $22,704,000. 96.71% of the stock is owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD opened at $28.45 on Friday. ACADIA Pharmaceuticals has a fifty-two week low of $19.69 and a fifty-two week high of $29.48. The company has a market capitalization of $4.87 billion, a price-to-earnings ratio of 12.82, a price-to-earnings-growth ratio of 19.47 and a beta of 0.81. The firm has a 50-day simple moving average of $24.24 and a 200-day simple moving average of $23.23.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.11. The firm had revenue of $308.00 million for the quarter, compared to analysts’ expectations of $296.55 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.The firm’s revenue for the quarter was up 16.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.16 EPS. Equities research analysts forecast that ACADIA Pharmaceuticals will post 0.4 EPS for the current year.

More ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: ACADIA beat second-quarter earnings and revenue estimates, driven by strong sales of Daybue and Nuplazid. The company also raised its 2026 revenue outlook, providing evidence of continued commercial momentum. ACAD Q2 Earnings and Revenues Beat, 2026 View Raised on Product Sales
• Positive Sentiment: Citizens JMP raised its price target from $35 to $36 and maintained a “market outperform” rating, implying additional upside from the stock’s referenced price level. Citizens JMP Raises ACADIA Price Target
• Positive Sentiment: Rising earnings estimates are providing another potential catalyst. Zacks said recent estimate revisions indicate ACADIA’s shares could continue moving higher, while HC Wainwright raised its Q3 2026 EPS forecast to $0.15 from $0.13 and its FY2027 forecast to $1.89 from $1.70. Can Acadia Run Higher on Rising Earnings Estimates?
• Neutral Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate to $0.20 from $0.21 but retained a “Hold” rating. The mixed revisions suggest improving longer-term expectations but limited near-term conviction. HC Wainwright ACADIA Estimates
• Positive Sentiment: Recent earnings-call materials and coverage highlighted the second-quarter results and product performance, reinforcing the market’s focus on ACADIA’s revenue growth and profitability trajectory. ACADIA Q2 2026 Earnings Call Transcript

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.